Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial
Short excerpt below. Click through to read at the original source.
Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease vaccine after a late-stage trial.